<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html dir="ltr" xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml">
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>

<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<!-- 
	This website is powered by TYPO3 - inspiring people to share!
	TYPO3 is a free open source Content Management Framework initially created by Kasper Skaarhoj and licensed under GNU/GPL.
	TYPO3 is copyright 1998-2015 of Kasper Skaarhoj. Extensions are copyright of their respective owners.
	Information and contribution at http://typo3.org/
-->



<title>INHN: Samuel Gershon: Brintellix  -  votioxetine</title>
<meta name="generator" content="TYPO3 4.5 CMS" />

<link rel="stylesheet" type="text/css" href="IMAGES/STYLESHEET_9B1E31873F2366.CSS?1645000983" media="all" />



<script src="IMAGES/JAVASCRIPT_93077BB238F3E1.JS?1645000982" type="text/javascript"></script>


<link href="IMAGES/LAYOUT_3COL_STANDARD.CSS" rel="stylesheet" type="text/css" /><!--[if lte IE 7]><link href="fileadmin/styles/patches/../01_layouts_basics/css/patches/patch_3col_standard.css" rel="stylesheet" type="text/css" /><![endif]-->
<meta name="DC.title" content="Samuel Gershon: Brintellix  -  votioxetine" />
<meta name="description" content="INHN" />
<meta name="DC.Description" content="INHN" />
<meta name="keywords" content="International Network for the History of Neuropsychopharmacology" />
<meta name="DC.Subject" content="International Network for the History of Neuropsychopharmacology" />
<meta name="copyright" content="Copyright INHN 2012-14" />
<meta name="DC.Rights" content="Copyright INHN 2012-14" />
<meta http-equiv="content-language" content="en" />
<meta name="DC.Language" scheme="NISOZ39.50" content="en" />
<link rev="made" href="mailto:inhn@inhn.org" />
<meta http-equiv="reply-to" content="inhn@inhn.org" />
<meta name="author" content="Gregers Wegener" />
<meta name="DC.Creator" content="Gregers Wegener" />
<meta name="rating" content="General" />
<meta name="date" content="2020-05-19T18:02:23+00:00" />
<meta name="DC.date" content="2020-05-19T18:02:23+00:00" />
<meta name="robots" content="index,follow" />
<meta name="revisit-after" content="7" />
<link rel="start" href="INDEX681A.HTM?id=1" />
<link rel="up" href="INDEXAF9F.HTM?id=355" />
<link rel="next" href="INDEXCD60.HTM?id=3191" />
<link rel="prev" href="INDEX3D6D.HTM?id=2322" />
<link rel="canonical" href="INDEX031F.HTM?id=3472" />



</head>
<body id="pageUID-3472">


<div id="page_margins">
	<div id="page">
		<div id="header"><div class="tx-macinasearchbox-pi1">
		
<form action="https://inhn.org/index.php?id=5&amp;L=0" method="post" name="searchform" id="searchform">
<input name="tx_indexedsearch[sword]" type="text" value="Enter search word..." onclick="this.value=''" onblur="this.value='Enter search word...'" /><br />
<input type="hidden" name="tx_indexedsearch[_sections]" value="0" />
<input type="hidden" name="tx_indexedsearch[pointer]" value="0" />
<input type="hidden" name="tx_indexedsearch[ext]" value="0" />
<input type="hidden" name="tx_indexedsearch[lang]" value="0" />
</form>

	</div>
	<div id="topnav"><a class="skip" href="#navigation" title="Direkt zur Navigation springen">Zur Navigation springen</a><span class="hideme">.</span><a class="skip" href="#content" title="Direkt zum Content springen">Zum Content springen</a><span class="hideme">.</span><a href="INDEX3A9F.HTM?id=6" target="_self">Sitemap</a>&nbsp;&#124;&nbsp;<a href="INDEXD61C.HTM?id=5" target="_self">Search</a>&nbsp;&#124;&nbsp;<a href="INDEX65E4.HTM?id=kontakt" target="_self">Contact</a>&nbsp;&#124;&nbsp;<a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a></div><a href="INDEX2999.HTM?id=202"><img class="headImg1" src="IMAGES/COMPANY_LOGO.GIF" alt="" title="Home" width="598" height="100" /></a></div>
		<div id="nav"><a id="navigation" name="navigation"></a><div id="nav_main" class="hlist"><ul><li><a href="INDEX2999.HTM?id=202" target="_self"><span>Home</span></a></li><li><a href="INDEX7EFD.HTM?id=479" target="_self"><span>Dictionary</span></a></li><li><a href="INDEX3E5C.HTM?id=374" target="_self"><span>Drugs</span></a></li><li><a href="INDEXDBB1.HTM?id=565" target="_self"><span>Photos</span></a></li><li><a href="INDEXD919.HTM?id=342" target="_self"><span>Profiles</span></a></li><li id="current"><a href="INDEXAF9F.HTM?id=355" target="_self"><span>Controversies</span></a></li><li><a href="INDEXD122.HTM?id=641" target="_self"><span>Discoveries</span></a></li><li><a href="INDEX1F24.HTM?id=384" target="_self"><span>Books</span></a></li><li><a href="INDEX3958.HTM?id=467" target="_self"><span>Biographies</span></a></li><li><a href="INDEX677F.HTM?id=642" target="_self"><span>Perspectives</span></a></li><li><a href="INDEX8C00.HTM?id=343" target="_self"><span>Archives</span></a></li><li><a href="INDEX06CB.HTM?id=368" target="_self"><span>Ebooks</span></a></li><li><a href="INDEXA1F1.HTM?id=1755" target="_self"><span>Collated</span></a></li><li><a href="INDEXDF25.HTM?id=4128" target="_self"><span>Multilingual Project</span></a></li><li><a href="INDEXABE4.HTM?id=3884" target="_self"><span>INHN Publisher</span></a></li></ul></div></div>
		<div id="main">
			<div id="teaser" class="clearfix"><div class="rootline">You are here: <a href="INDEXAF9F.HTM?id=355" target="_self">Controversies</a>&nbsp;/&nbsp;Samuel Gershon: Brintellix  -  votioxetine</div><div class="langMenu"><div class="tx-srlanguagemenu-pi1">
		
	</div>
	</div></div>
			<div id="col1">
				<div id="col1_content" class="clearfix">
					<ul id="submenu"><li id="title">Controversies</li><li><a href="INDEX01FF.HTM?id=3395" target="_self">Jay D. Amsterdam and Leemon B. McHenry: The Paroxetine 352 Bipolar Study Revisited: Deconstruction of Corporate and Academic Misconduct.</a><span class="hidden">.</span></li><li><a href="INDEXC230.HTM?id=486" target="_self">Thomas A. Ban: Conflict of interest in neuropsychopharmacology</a><span class="hidden">.</span></li><li><a href="INDEX2AF5.HTM?id=1342" target="_self">Thomas A. Ban: Development of our Vocabulary</a></li><li><a href="INDEX1BE7.HTM?id=3220" target="_self">Thomas A. Ban:  Education in Biological Psychiatry – Homage to Dr. Heinz E. Lehmann</a></li><li><a href="INDEXFB00.HTM?id=829" target="_self">Barry Blackwell: Adumbration; A history lesson</a><span class="hidden">.</span></li><li><a href="INDEX7196.HTM?id=3970" target="_self">Barry Blackwell: A Tale of Two Pioneers.</a></li><li><a href="INDEXD39F.HTM?id=1665" target="_self">Barry Blackwell: Corporate Corruption in the Psychopharmaceutical Industry</a><span class="hidden">.</span></li><li><a href="INDEXF833.HTM?id=1944" target="_self">Barry Blackwell: Corporate Corruption in the Psychopharmaceutical Industry. Revised</a><span class="hidden">.</span></li><li><a href="INDEX8B56.HTM?id=778" target="_self">Barry Blackwell: The anxiety enigma</a><span class="hidden">.</span></li><li><a href="INDEX8B7A.HTM?id=2096" target="_self">Barry Blackwell: The Baby and The Bath Water</a><span class="hidden">.</span></li><li><a href="INDEX07C2.HTM?id=622" target="_self">Barry Blackwell: The lithium controversy: A historical autopsy</a><span class="hidden">.</span></li><li><a href="INDEX12D3.HTM?id=1369" target="_self">Pierre Baumann and Francois Ferrero: An official inqury of the clinical research activities (1946-1972) of Roland Kuhn (1912-2005)</a><span class="hidden">.</span></li><li><a href="INDEXA7C8.HTM?id=2954" target="_self">John Court: A note on the history of Anorexia Nervosa</a></li><li><a href="INDEX32F0.HTM?id=421" target="_self">Paul Devenyi: Addictions are not treatable diseases</a><span class="hidden">.</span></li><li><a href="INDEXE29D.HTM?id=477" target="_self">Paul Devenyi: Pharmacotherapy of addictions</a></li><li><a href="INDEXC591.HTM?id=3315" target="_self">Camille Drach Hojaij: Stein and Empathic Fulfilment.</a><span class="hidden">.</span></li><li><a href="INDEX3CB5.HTM?id=2526" target="_self">François Ferrero: Inquiry of the Geneva 1980s’ Psychiatry Crisis</a><span class="hidden">.</span></li><li><a href="INDEXC947.HTM?id=3727" target="_self">Max Fink: Reconceptualization of Catatonia.</a><span class="hidden">.</span></li><li><a href="INDEX3D6D.HTM?id=2322" target="_self">Ernst J. Franzek: From the dichotomy to a three-part grouping of endogenous psychoses</a><span class="hidden">.</span></li><li><strong>Samuel Gershon: Brintellix  -  votioxetine</strong></li><li><a href="INDEXCD60.HTM?id=3191" target="_self">Samuel Gershon: Device for naltrexone delivery</a></li><li><a href="INDEX8E42.HTM?id=3064" target="_self">Samuel Gershon: Ketamine, the “new” breakthrough in the treatment of depression</a><span class="hidden">.</span></li><li><a href="INDEX1823.HTM?id=2488" target="_self">Samuel Gershon: Lithium history</a><span class="hidden">.</span></li><li><a href="INDEX5D83.HTM?id=3646" target="_self">Samuel Gershon: The emergence of “new” drugs in recent years.</a></li><li><a href="INDEXFA6F.HTM?id=3375" target="_self">Samuel Gershon: The Tacrine paradigm.</a><span class="hidden">.</span></li><li><a href="INDEXF3E3.HTM?id=670" target="_self">Samuel Gershon: The trazodone cntrovery and its potential fatal consequences</a></li><li><a href="INDEX4A93.HTM?id=2894" target="_self">Ken Gillman: Medical science publishing: A slow-motion train wreck</a><span class="hidden">.</span></li><li><a href="INDEXDBE8.HTM?id=3720" target="_self">David Healy: Do Randomized Controlled Trials Add to or Subtract from Clinical Knowledge?</a><span class="hidden">.</span></li><li><a href="INDEX3202.HTM?id=1350" target="_self">David Healy: The shipwreck of the singular</a><span class="hidden">.</span></li><li><a href="INDEX2555.HTM?id=2447" target="_self">Hanfried Helmchen: The role of psychopharmacotherapy in the early development of social psychiatry in Germany</a><span class="hidden">.</span></li><li><a href="INDEXE41A.HTM?id=2095" target="_self">Carlos R. Hojaij: A Psychopathological Marker For Biological Psychiatry:  The Point of No Return and the “Something New&quot; *</a></li><li><a href="INDEX4C30.HTM?id=1823" target="_self">Carlos R. Hojaij: “DSM-5: The Future of Psychiatric Diagnosis” or Continuing the Psychiatry DiSMantlement</a><span class="hidden">.</span></li><li><a href="INDEX14F7.HTM?id=2103" target="_self">Carlos R. Hojaij: Psychiatry and Medicine</a></li><li><a href="INDEX711C.HTM?id=2118" target="_self">Carlos R. Hojaij: Towards a Psychiatric Biology</a></li><li><a href="INDEX61B8.HTM?id=3147" target="_self">David Janowsky: Cholinergic muscarinic mechanisms in depression and mania</a><span class="hidden">.</span></li><li><a href="INDEXC12C.HTM?id=3956" target="_self">Daniel Kanofsky and Mary E. Woesner: A Fresh Air Approach to COVID-19.</a><span class="hidden">.</span></li><li><a href="INDEX0B8F.HTM?id=530" target="_self">Martin M. Katz: Component-Specific vs. Diagnosis-Specific Clinical Trial in Depression</a><span class="hidden">.</span></li><li><a href="INDEXBDA3.HTM?id=594" target="_self">Martin M. Katz: Multivantaged vs. conventional assessment method</a><span class="hidden">.</span></li><li><a href="INDEX46C5.HTM?id=496" target="_self">Martin M. Katz: Onset of clinical action of antidepressants</a><span class="hidden">.</span></li><li><a href="INDEX94E9.HTM?id=1147" target="_self">Martin  M. Katz: The need and rationale for shortenng the clinical trial for antidepressants</a></li><li><a href="INDEXB724.HTM?id=2329" target="_self">Donald F. Klein, Max Fink, Edward Shorter and Thomas A. Ban: Comment exchange on Flagrant Catatonic Behavior.</a><span class="hidden">.</span></li><li><a href="INDEXA16A.HTM?id=1625" target="_self">Joseph Knoll: Controversies on selegiline/(-)-deprenyl’s  pharmacological spectrum after more than 50 years of its development</a></li><li><a href="INDEX98B4.HTM?id=2771" target="_self">Magda Malewska-Kasprzak, Agnieszka Permoda-Osip, Janusz Rybakowski:Disturbances of the purinergic system in affective disorders and schizophrenia</a><span class="hidden">.</span></li><li><a href="INDEXBB29.HTM?id=4134" target="_self">Trudo Lemmens. “Medical Assistance in Dying” (Euthanasia and Assisted Suicide) in Canada: A Case Raises Questions About Its Use in Patients with Disability and Mental Illness.</a><span class="hidden">.</span></li><li><a href="INDEXEBA9.HTM?id=3891" target="_self">Amy S. F. Lutz: The Rise and Fall of the Dexamethasone Suppression Test: Stability, Consensus, Closure.</a><span class="hidden">.</span></li><li><a href="INDEX41D4.HTM?id=3252" target="_self">Gin S. Malhi: A critical analysis of concepts in psychiatry</a><span class="hidden">.</span></li><li><a href="INDEXD25B.HTM?id=2701" target="_self">Antonio E. Nardi, Richard Balon, Guy Chouinard, Fiammetta Cosci, Steven Dubovsky, Giovanni A. Fava, Rafael C. Freire, David J. Greenblatt, John H. Krystal, Karl Rickels, Thomas Roth, Carl Salzman, Richard I. Shader, Edward K. Silberman, Nicoletta Sonino,</a><span class="hidden">.</span></li><li><a href="INDEX4CFC.HTM?id=2972" target="_self">János Radó: Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment</a><span class="hidden">.</span></li><li><a href="INDEXD26F.HTM?id=3140" target="_self">Janos Radó: Desmopressin may counteract polyuria in lithium-induced nephrogenic diabetes insipidus. Review of the literature</a><span class="hidden">.</span></li><li><a href="INDEX13F5.HTM?id=1248" target="_self">Shridhar Sharma: Insulin coma treatment: Facts and controversies</a><span class="hidden">.</span></li><li><a href="INDEX5461.HTM?id=390" target="_self">Edward Shorter: The Q-T interval and the Mellaril story - a cautionary tale</a><span class="hidden">.</span></li><li><a href="INDEX70B9.HTM?id=2755" target="_self">Leonardo Tondo: Brief History of Suicide in Western Cultures</a><span class="hidden">.</span></li><li><a href="INDEX7938.HTM?id=2000" target="_self">Hector Warnes: The gut-brain axis</a><span class="hidden">.</span></li><li><a href="INDEXEABE.HTM?id=3450" target="_self">Hector Warnes: Pyridoxine in the treatment of lithium-induced tremor.</a><span class="hidden">.</span></li></ul>
					
					<div class="textBelowMenu"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
				</div>
			</div>
			<div id="col2">
				<div id="col2_content" class="clearfix"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
			</div>
			<div id="col3">
			  <a id="content" name="content"></a>
				<div id="col3_content" class="clearfix">
					<div class="floatbox"><!--TYPO3SEARCH_begin--><div id="c5273" class="csc-default"><h1>Samuel Gershon: Brintellix &nbsp;- &nbsp;votioxetine</h1>
<p>&nbsp;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; My information on Brintellix&nbsp; (votioxetine) is limited and confusing. I received my initial information from the company advertisements and brief clinical statements about it.<br />From my scrappy information, it seems that this compound has been approved for sale in the US with an indication that seems to focus on the claim that this compound is uniquely beneficial for postpartum depression. (It has also been approved for sale in Australia.) The claim of very prompt anti-depressant efficacy in this special population provided special interest in early approval. Also, in reading some more advertisements it also appears that Brintellix will prevent the recurrence of subsequent depressive episodes. Additionally, one of the side effects listed is the occurrence of a manic illness. Just at this point it would help if the company might indicate whether it would be contraindicated in bipolar patients altogether.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ken Gillman sent me his 2016 article on this substance in which he addresses more clearly than I a number of questions and concerns that I have about the clinical data and how well these claims are substantiated.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Although I have little information on this compound, some aspects of the story are similar to the questions that have been raised about the Ketamines (Gershon 2019).<br />There seems to be an indication that the FDA is including in the approval evaluations things like the uniqueness of these compounds and their rapidity of production of a positive outcome.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; So, after just reading Jay Amsterdam’s input to the article published by Edward Tobe (2020), I am offering these other questions with a lot of concern about what is going on with these new wonder drugs. They are spreading into clinical usage very rapidly and I would welcome opinions from my colleagues.</p>
<p>&nbsp;</p>
<p><b>References:</b></p>
<p>Gershon S. Ketamine, the “new” breakthrough in the treatment of depression. inhn.org.controversies. July 18, 2019.</p>
<p>Gillman K. Vortioxetine: Multimodal or Multi-muddle. https://psychotropical.com/vortioxetine-multimodal-or-multi-muddle/. 2016.</p>
<p>Tobe EH. The Iceberg of Improbity.&nbsp; Journal of Scientific Practice and Integrity. 2020; 2(1).</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>May 21, 2020</p></div><!--TYPO3SEARCH_end--></div>
				</div>
				<div id="ie_clearing">&nbsp;</div>
			</div>
		</div>
		<div id="footer">&copy; INHN 2012-2022 ::: INHN Central Office  · Av. Sagrada Familia Esq Nazaret · Córdoba, Córdoba X5000 · Argentina  ::: email: inhn@inhn.org</div>
	</div>
</div>





<script src="IMAGES/URCHIN.JS" type="text/javascript">
</script>
<script type="text/javascript">
_uacct = "UA-39727086-1";
urchinTracker();
</script>
</body>
</html>